Use of Rituximab in Patients with Follicular Lymphoma

Clinical Oncology

Volumn 19, Issue 1, 2007, Pages 38-49

  Marcus, R ^a  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

Chemotherapy; follicular lymphoma; monoclonal antibodies; rituximab

Indexed keywords

CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; INTERFERON; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADVANCED CANCER; ARTICLE; CANCER MORTALITY; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG HYPERSENSITIVITY; DRUG RESPONSE; FOLLICULAR LYMPHOMA; HUMAN; IMMUNOTHERAPY; MAINTENANCE THERAPY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; DOXORUBICIN; HUMANS; LYMPHOMA, FOLLICULAR; MITOXANTRONE; PREDNISOLONE; PREDNISONE; RANDOMIZED CONTROLLED TRIALS; RECURRENCE; VINCRISTINE;

EID: 33846010177     PISSN: 09366555     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clon.2006.11.009     Document Type: Article

References (64)

1. Horning S.J. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol 20 (1993) 75-88
2. Solal-Celigny P.H. Management of histologically indolent non-Hodgkin's lymphomas. Baillieres Clin Haematol 9 (1996) 669-687
3. Aisenberg A.C. Coherent view of non-Hodgkin's lymphoma. (review). J Clin Oncol 13 (1995) 2656-2675
4. Lister T.A., Cullen M.H., Beard M.E., et al. Comparison of combined and single-agent chemotherapy in non-Hodgkin's lymphoma of favourable histological type. Br Med J 1 (1978) 533-537
5. Hoppe R.T., Kushlan P., Kaplan H.S., Rosenberg S.A., and Brown B.W. The treatment of advanced stage favorable histology non-Hodgkin's lymphoma: a preliminary report of a randomised trial comparing single agent chemotherapy, combination chemotherapy, and whole body irradiation. Blood 58 (1981) 592-598
6. Kimby E., Bjorkholm M., Gahrton G., et al. Chlorambucil/prednisone vs CHOP in symptomatic low-grade non-Hodgkin's lymphomas: a randomized trial from the Lymphoma Group of Central Sweden. Ann Oncol 5 Suppl 2 (1994) S67-S71
7. Peterson B.A., Petroni G.R., Frizzera G., et al. Prolonged single-agent versus combination chemotherapy in indolent follicular lymphomas: a study of the cancer and leukemia group B. J Clin Oncol 21 (2003) 5-15
8. Portlock C.S., Rosenberg S.A., Glatstein E., and Kaplan H.S. Treatment of advanced non-Hodgkin's lymphomas with favorable histologies: preliminary results of a prospective trial. Blood 47 (1976) 747-756
9. Solal-Celigny P., Lepage E., Brousse N., et al. Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial. J Clin Oncol 16 (1998) 2332-2338
10. Lenz G., Dreyling M., Schiegnitz E., et al. Myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission prolongs progression-free survival in follicular lymphoma: results of a prospective, randomized trial of the German Low-grade Lymphoma Study Group. Blood 104 (2004) 2667-2674
11. Brice P., Simon D., Bouabdallah R., et al. High-dose therapy with autologous stem-cell transplantation (ASCT) after first progression prolonged survival of follicular lymphoma patients included in the prospective GELF 86 protocol. Ann Oncol 11 (2000) 1585-1590
12. Deconinck E., Foussard C., Milpied N., et al. High dose therapy followed by autologous purged stem cell transplantation and doxorubicin based chemotherapy in patients with advanced follicular lymphoma: a randomized multicenter study by the GOELAMS. Blood 105 (2005) 3817-3823
13. Coiffier B., Fougier P., Sebban C., et al. Long term results of the GELA study, R-CHOP vs CHOP in elderly patients with diffuse large B-cell lymphoma. Blood 104 (2004) 388a (abstract 1383)
14. McLaughlin P., Grillo-Lopez A.J., Link B.K., et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16 (1998) 2825-2833
15. McLaughlin P., Hagemeister F.B., and Grillo-López A.J. Rituximab in indolent lymphoma: the single-agent pivotal trial. Semin Oncol 26 Suppl 14 (1999) 79-87
16. Colombat P., Salles G., Brousse N., et al. Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation. Blood 97 (2001) 101-106
17. Solal-Celigny P., Salles G.A., Brousse N., et al. Single 4-dose rituximab treatment for low-tumor burden follicular lymphoma (FL): survival analyses with a follow-up (F/Up) of at least 5 years. Blood 104 (2004) 169a (abstract 585)
18. Witzig T.E., Vukov A.M., Habermann T.M., et al. Rituximab therapy for patients with newly diagnosed, advanced-stage, follicular grade I non-Hodgkin's lymphoma: a phase II trial in the North Central Cancer Treatment Group. J Clin Oncol 23 (2005) 1103-1108
19. Ardeshna K.M., Smith P., Norton A., et al. Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial. Lancet 362 (2003) 516-522
20. Davis T.A., Grillo-Lopez A.J., White C.A., et al. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment. J Clin Oncol 18 (2000) 3135-3143
21. Lemieux B., Bouafia F., Thieblemont C., et al. Second treatment with rituximab in B-cell non-Hodgkin's lymphoma: efficacy and toxicity on 41 patients treated at CHU-Lyon Sud. Hematol J 5 (2004) 467-471
22. Weide R., Heymanns J., Koeppler H., et al. Bendamustine/mitoxantrone/rituximab (BMR): a very effective and well tolerated immuno-chemotherapy for relapsed and refractory indolent lymphomas - high response rate in patients pretreated with rituximab - results of a multicentre phase-II-study of the German Low Grade Lymphoma Study Group (GLSG). Proc Am Soc Clin Oncol 23 (2005) 589s (abstract 6616)
23. Demidem A., Lam T., Alas S., Hariharan K., Hanna N., and Bonavida B. Chimeric anti-CD20 (IDEC-C2B8) monoclonal antibody sensitizes a B cell lymphoma cell line to cell killing by cytotoxic drugs. Cancer Biother Radiopharm 12 (1997) 177-186
24. Di Gaetano N., Xiao Y., Erba E., et al. Synergism between fludarabine and rituximab revealed in a follicular lymphoma cell line resistant to the cytotoxic activity of either drug alone. Br J Haematol 114 (2001) 800-809
25. Alas S., and Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 61 (2001) 5137-5144
26. Czuczman M.S., Grillo-Lopez A.J., White C.A., et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 17 (1999) 268-276
27. Czuczman M.S., Weaver R., Alkuzweny B., Berlfein J., and Grillo-Lopez A.J. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 22 (2004) 4711-4716
28. Hainsworth J.D., Litchy S., Morrissey L.H., et al. Rituximab plus short duration chemotherapy as first-line treatment for follicular non-Hodgkin's lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 23 (2005) 1500-1506
29. McLaughlin P., Rodriguez M.A., Hagemeister F.B., et al. Stage IV indolent lymphoma: a randomized study of concurrent vs sequential use of FND chemotherapy (fludarabine, mitoxantrone, dexamethasone) and rituximab (R) monoclonal antibody therapy, with interferon maintenance. Proc Am Soc Clin Oncol 22 (2003) 564 (abstract 2269)
30. van Oers M.H.J., Klasa R., Marcus R.E., et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin's lymphoma, both in patients with and without rituximab during induction: results of a prospective randomized phase III intergroup trial. Blood 108 10 (2006) 3295-3301
31. Forstpointner R., Dreyling M., Repp R., et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared to FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas - results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 104 (2004) 3064-3071
32. Solal-Celigny P., Imrie K., Belch A., et al. MabThera (Rituximab) plus CVP chemotherapy for first-line treatment of stage III/IV follicular non-Hodgkin s lymphoma (NHL): confirmed efficacy with longer follow-up. Blood 106 (2005) 106a (abstract 350)
33. Herold M., Pasold R., Srock S., et al. Rituximab plus mitoxantrone, chlorambucil, prednisolon (R-MCP) is superior to MCP alone in advanced indolent and follicular lymphoma - results of a phase III study (OSHO39). Ann Oncol 16 Suppl 5 (2005) v51-v52 (abstract 060)
34. Hiddemann W., Kneba M., Dreyling M., et al. Front-line therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) significantly improves the outcome of patients with advanced stage follicular lymphomas as compared to CHOP alone - results of a prospective randomized study of the German low grade lymphoma study group (GLSG). Blood 106 (2005) 3725-3732
35. Foussard C., Mounier N., Van Hoof A., et al. Update of the FL2000 randomized trial combining rituximab to CHVP-interferon in follicular lymphoma (FL) patients (pts). J Clin Oncol 24 18S (2006) 424s (abstract 7508)
36. Marcus R., Imrie K., Belch A., et al. CVP chemotherapy plus rituximab compared with CVP as first-line treatment for advanced follicular lymphoma. Blood 105 (2005) 1417-1423
37. Imrie K., Belch A., Pettengell R., et al. CVP plus rituximab compared to CVP alone in previously untreated patients with follicular lymphoma: impact of baseline prognostic factors. Ann Oncol 16 Suppl 5 (2005) v109-v110 (abstract 249) [and updated from poster presentation]
38. Cunningham D., Aultman R., Jost F., and Marcus R. Q-TWiST analysis of rituximab plus CVP versus CVP alone as first-line treatment for advanced follicular lymphoma. Haematologica 90 S2 (2005) 274 (abstract 685)
39. Hiddemann W., Dreyling M.H., Fortspointner R., et al. Combined immunochemotherapy (R-CHOP) significantly improves time to treatment failure in first-line therapy of follicular lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Blood 102 (2003) 104a (abstract 352)
40. Buske C., Hoster E., Dreyling M., et al. The Follicular Lymphoma International Prognostic Index (FLIPI) separates high risk from intermediate or low risk patients with advanced stage follicular lymphoma treated front-line with rituximab and the combination of cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with respect to treatment outcome. Blood 108 (2006) 1504-1508
41. Salles G.A., Foussard C., Mounier N., et al. Rituximab added to αIFN+CHVP improves the outcome of follicular lymphoma patients with a high tumor burden: first analysis of the GELA-GOELAMS FL-2000 randomized trial in 359 patients. Blood 104 (2004) 49a (abstract 160)
42. Herold M., Pasold R., Srock S., et al. Results of a prospective randomized open label phase III study comparing rituximab plus mitoxantrone, chlorambucil, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-Hodgkin's lymphoma (NHL) and mantle-cell-lymphoma (MCL). Blood 104 (2004) 169a (abstract 584)
43. Schulz H., Skoetz N., Bohlius J., et al. Does combined immunochemotherapy with the monoclonal antibody Rituximab improve overall survival in the treatment of patients with indolent non-Hodgkin lymphoma? Preliminary results of a comprehensive meta-analysis. Blood 106 (2005) 106A (abstract 351)
44. Hagenbeek A., Van Glabbeke M., Teodorovic I., et al. The role of rituximab maintenance treatment in relapsed follicular NHL: an interim analysis of the EORTC randomized intergroup trial. Ann Oncol 16 Suppl 5 (2005) v52 (abstract 061)
45. Dreyling M., Forstpointner R., Ludwig W., et al. The addition of rituximab to a fludarabine combination (R-FCM) significantly improves remission rates and overall survival in recurrent follicular as well as mantle cell lymphoma - follow-up of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). Ann Oncol 16 Suppl 5 (2005) v110 (abstract 252)
46. Dreyling M., Forstpointner R., Gramatzki M., et al. Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (R-FCM) in patients with relapsed follicular and mantle cell lymphoma: final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 24 18S (2006) 422s (abstract 7502)
47. Hochster H.S., Weller E., Ryan T., et al. Results of E1496: a phase III trial of CVP with or without maintenance rituximab in advanced indolent lymphoma (NHL). J Clin Oncol 22 (2004) 558s (abstract 6502) [updated in oral presentation]
48. Hochster H.S., Weller E., Gascoyne R.D., et al. Maintenance rituximab after CVP results in superior clinical outcome in advanced follicular lymphoma (FL): results of the E1496 phase III trial from the Eastern Cooperative Oncology Group and the Cancer and Leukemia Group B. Blood 106 (2005) 106a (abstract 349)
49. Hainsworth J.D., Litchy S., Shaffer D.W., Lackey V.L., Grimaldi M., and Greco F.A. Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma - a randomized phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 23 (2005) 1088-1095
50. Ghielmini M., Schmitz S.-F.H., Cogliatti S.B., et al. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly × 4 schedule. Blood 103 (2004) 4416-4423
51. Cartron G., Dacheux L., Salles G., et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood 99 (2002) 754-758
52. Maloney D., Pender-Smith B., Unger J., et al. Fcγ receptor polymorphisms do not influence progression free survival (PFS) of follicular NHL patients treated with CHOP followed by rituximab (SWOG 9800). Blood 104 (2004) 170a (abstract 589)
53. Boettcher S., Pott C., Ritgen M., Hiddemann W., Unterhalt M., and Kneba M. Evidence for FCγ receptorIIIA-independent rituximab effector mechanisms in patients with follicular lymphoma treated with combined immuno-chemotherapy. Blood 104 (2004) 170a (abstract 590)
54. Witzig T.E. Radioimmunotherapy for patients with relapsed B-cell non-Hodgkin lymphoma. Cancer Chemother Pharmacol 48 Suppl 1 (2001) S91-S95
55. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med 352 (2005) 441-449
56. ®) for front-line treatment of advanced stage, follicular lymphoma: Southwest Oncology Group Protocol 9911. Blood 106 (2005) 107a (abstract 352)
57. O'Connor O.A., Wright J., Moskowitz C., et al. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 23 (2005) 676-684
58. Bowles J.A., Wang S.Y., Link B.K., et al. Anti-CD20 monoclonal antibody with enhanced affinity for CD16 activates NK cells at lower concentrations and more effectively than rituximab. Blood (2006) (epub ahead of print)
59. Kimby E., Geisler C., Hagberg H., et al. Rituximab as single agent and in combination with interferon-α-2a as treatment of untreated and first relapse follicular or other low-grade lymphomas. A randomized phase II study. Ann Oncol 13 Suppl 2 (2002) 85 (abstract 289)
60. Goy A., Younes A., McLaughlin P., et al. Phase II study of proteasome inhibitor bortezomib in relapsed or refractory B-cell non-Hodgkin's lymphoma. J Clin Oncol 23 (2005) 667-675
61. Lewintre E.J., Sarsotti E., Terol M.J., et al. Treatment of B-CLL cells with bortezomib and rituximab reduces cell viability in vitro. Blood 104 (2004) 765a (abstract 2798)
62. Santos C., Stern L., Katz L., et al. BiovaxID™ vaccine therapy of follicular lymphoma in first remission: long-term follow-up of a phase II trial and status of a controlled, randomized phase III trial. Blood 106 (2005) 686a (abstract 2441)
63. Dave S.S., Wright G., Tan B., et al. Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. N Engl J Med 351 (2004) 2159-2169
64. Solal-Celigny P., Roy P., Colombat P., et al. Follicular lymphoma international prognostic index. Blood 104 (2004) 1258-1265